Communities in GERR
Select a community to browse its collections.
Featured Items
Recent Submissions
Publication Metadata only Holding Space 1: Understanding Sexual Violence and the Perinatal Period(All4holdings, 2026-01-01)No abstract availablePublication Metadata only Holding Space 3: Legislative Perspectives on Sexual Violence(All4holdings, 2026-07-01)Sexual violence is perpetuated by sociocultural inequality. Legal and policy frameworks shape how it is defined, addressed and responded to. In this article, the third in a five-part series, the United Kingdom's (UK) legislative response to sexual violence and its relevance to midwifery practice, ethical decision making and advocacy is examined. The first article outlined legal definitions of sexual offences and perinatal impact; the second explored sociocultural drivers.Publication Metadata only 245 - Proactive physiotherapy: an innovative approach to reduce sickness absence and presenteeism within the NHS workforce(Elsevier, 2026-07-24)Purpose: Traditional physiotherapy is reactive. Our service focuses on proactive interventions; supporting the government and NHS strategic frameworks' push for preventative healthcare. Before implementation, we analysed national statistics and real-time data from our trust to understand the scale of MSK related absence. We monitored occupational health referrals, identifying departments with high musculoskeletal (MSK) cases, allowing for targeted interventions. Additionally, we used data from the NHS staff survey and pulse surveys at trust level to assess staff perceptions of their health and wellbeing. This, combined with department-level staff scoping, helped identify unique challenges across teams.Publication Open Access Eye movement desensitisation and reprocessing for post-traumatic stress in survivors of critical illness (EMERALD): a mixed-methods, randomised, single-blind, parallel group-controlled, feasibility trial(Elsevier, 2026-07-13)Background: Eye movement desensitisation and reprocessing (EMDR) is a guideline-recommended treatment for post-traumatic stress disorder (PTSD), but evidence in survivors of critical illness remains limited. We assessed the feasibility, acceptability, and safety of EMDR for critical care survivors with clinically significant post-traumatic stress symptoms, and generated exploratory clinical outcome estimates to inform a future definitive trial. Methods: We conducted a mixed-methods, randomised, single-blind, parallel group-controlled, feasibility trial at three UK National Health Service hospitals. Adults (≥18 years) with an intensive care stay >24 h were approached before hospital discharge and followed within an observational cohort. At 2-3 months, participants were screened for post-traumatic stress symptoms (Impact of Event Scale-Revised); those scoring ≥22 were invited and randomly assigned (1:1) to EMDR plus treatment as usual (TAU) or TAU. EMDR comprised up to 16 sessions delivered face-to-face or online by accredited therapists. Primary outcomes were feasibility (recruitment, retention, intervention uptake, fidelity) and safety. Symptoms were assessed using Clinician-administered PTSD Scale for Diagnostic and Statistical Manual-5 (CAPS-5) at 3 and 12 months. Analyses followed intention-to-treat principles. The trial was registered on ClinicalTrials.gov (NCT05591625) and is closed to recruitment. Findings: Between Feb 20, 2023, and May 13, 2024, 160 patients were recruited to the observational cohort; 40 were randomised, with 20 allocated to EMDR plus TAU and 20 to TAU. Median age was 59.5 years (IQR 52.0-66.0); 21 participants (53%) were female and 19 (48%) were male. At 12 months, 39 (98%, 95% CI 86.8-99.9) of 40 randomised participants completed CAPS-5 follow-up. In the EMDR plus TAU group, 18 (90%, 95% CI 68.3-98.8) of 20 participants initiated treatment; mean sessions attended was 10.4 (SD 7.0), and 15 (75%) of 20 completed a full therapeutic course. Mean CAPS-5 score change was -15.6 (SD 12.5) in the EMDR plus TAU group and -1.6 (SD 11.8) in the TAU group, giving an exploratory unadjusted between-group difference of -14.1 points (95% CI -22.0 to -6.2). No treatment-related serious adverse events were identified. Interpretation: A staged trial pathway of symptom screening, clinician-rated PTSD assessment, randomisation, and EMDR delivery was feasible and broadly acceptable in survivors of critical illness with clinically significant post-traumatic stress symptoms. Exploratory clinician-rated PTSD outcome estimates were hypothesis-generating and support progression to a definitive multicentre trial, but should not be interpreted as evidence of treatment effectiveness. Funding: Andrew Bates was funded by National Institute for Health and Care Research Clinical Doctoral Research fellowship (grant number: NIHR302160). Keywords: Critical illness; Eye movement desensitization reprocessing; Feasibility studies; Intensive care units; Post-traumatic; Stress disorders; Survivors.Publication Open Access Early Treatment-Related Mortality in Acute Leukemia: A Real-World, Single-Center Study From a Resource-Limited Setting(Springer Nature, 2026-06-21)Background and objectives Treatment-related mortality (TRM) remains a significant barrier to successful outcomes in acute leukemia despite therapeutic advances. This study aimed to evaluate the frequency, clinical features, and risk factors associated with early TRM in a real-world cohort from a resource-limited setting, defined as death occurring within 30 days of treatment initiation. The primary aims of this study were to evaluate the incidence and timing of early death (ED) and TRM across different blood cancer classifications. The secondary aim was to identify the specific clinical causes, such as infectious complications, hemorrhagic events, or refractory disease, that drive these fatalities. Methods We retrospectively analyzed 155 patients aged 14 to 100 years diagnosed with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), acute promyelocytic leukemia (APL), or acute undifferentiated leukemia (AUL) between 2016 and 2025 at a single tertiary center in Iraq. Patients received standard treatment protocols, including the 3+7 regimen, UKALL XC, ATRA/ATO (all-trans retinoic acid and arsenic trioxide), hyper-CVAD (hyper-fractionated cyclophosphamide, vincristine, adriamycin, and dexamethasone), azacitidine, ATRA/idarubicin, and others. Results The overall TRM rate was 9.0% (14/155). APL patients demonstrated the highest mortality at 28.6% (8/28), followed by ALL at 5.1% (3/59), and AML at 4.5% (3/66). Female patients accounted for 78.6% of deaths. The principal causes were sepsis (42.9%), differentiation syndrome (28.6%), intracranial hemorrhage (21.4%), and alveolar hemorrhage (7.1%). No statistically significant differences in clinical parameters were observed between patients with ED and those without ED. Conclusions TRM rates remain substantial, particularly among APL patients, with infection representing the predominant cause. These real-world findings highlight the need for early risk recognition, rapid supportive care, and improved treatment pathways for acute leukemia in resource-limited settings. Keywords: acute leukemia; acute promyelocytic leukemia; early death; induction chemotherapy; treatment-related mortality.
